102083-3 |
Arginine Stimulation XXX Challenge Panel |
- |
Ser/Plas |
Pt |
- |
IA |
|
ACTIVE |
Arginine stimulation challenge panel - Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHAL |
|
102083-3 |
|
IA |
|
|
Order |
|
|
|
0 |
Arginine stim chal pnl SerPl IA |
|
|
|
N |
|
Arg; Arginine stim chal pnl; CHEMISTRY.CHALLENGE TESTING; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; MEIA; Pan; PANEL.CHALLENGE; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Stim; SUDS |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
102084-1 |
B-Cell lymphoblastic leukemia monitoring minimal residual disease detection |
- |
Bld/Bone mar |
Pt |
- |
Flow cytometry |
|
ACTIVE |
B-Cell lymphoblastic leukemia monitoring minimal residual disease detection in Blood or Marrow by Flow cytometry (FC) |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CELLMARK |
|
102084-1 |
|
Flow cytometry |
|
|
Order |
|
|
|
0 |
BCell Lym LK monitor MRD det Bld/Mar FC |
|
|
|
N |
|
B Cell; B-ALL; B-cell acute lymphoblastic leukemia; BCell Lym LK monitor MRD det; BCELLS; Bld/Mar; Blood; BM; BON; Bone marrow; CELL MARKERS; Dis; Diseases; Dynamic; Dz; FC; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; Pan; Panel; PANEL.CELLMARK; Panl; Pnl; Point in time; Random; WB; Whole blood; Whole blood or Bone marrow |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
102085-8 |
CNS demyelinating disease panel |
- |
Ser/Plas |
Pt |
- |
Flow cytometry |
|
ACTIVE |
CNS Demyelinating Disease Panel - Serum or Plasma by Flow cytometry (FC) |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MOLPATH |
|
102085-8 |
|
Flow cytometry |
|
|
Order |
|
|
|
0 |
CNS Demyelinating ds Panel SerPl FC |
|
|
|
N |
|
CNS Demyelinating ds Panel; Dis; Diseases; Dynamic; Dz; FC; Molecular pathology; MOLPATH; Pan; Panel.molpath; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
102086-6 |
Endometrial stromal tumor |
Find |
Tiss |
Pt |
Doc |
FISH |
|
ACTIVE |
Endometrial stromal tumor in Tissue Document by FISH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
102086-6 |
|
FISH |
|
|
Both |
|
|
|
0 |
Endometrial stromal tumor Tiss Doc FISH |
|
|
|
N |
|
Document; Finding; Findings; Fluorescent in situ hybridization; Pathology; Point in time; Random; Tissue; Tissue, unspecified |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
102087-4 |
Gastrin secretin stimulation XXX challenge panel |
- |
Ser |
Pt |
- |
|
|
ACTIVE |
Secretin stimulation/Gastrin XXX challenge panel |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHAL |
|
102087-4 |
|
|
|
|
Order |
|
|
|
0 |
Secretin stim/Gastrin chal pnl Ser |
|
|
|
N |
|
CHEMISTRY.CHALLENGE TESTING; Gastrin secretin stim XXX chal pnl; Pan; PANEL.CHALLENGE; Panl; Pnl; Point in time; Random; Secretin stim chal pnl; Serum; SR; Stim; Total gastrins; Zollinger-Ellison syndrome |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
102088-2 |
Torch Ab.IgG panel |
- |
Ser |
Pt |
- |
|
|
ACTIVE |
Torch Ab.IgG panel - Serum |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
102088-2 |
|
|
|
|
Order |
|
|
|
0 |
Torch IgG pnl Ser |
|
|
|
N |
|
Immune globulin G; Immunoglobulin G; Microbiology; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; Random; Serum; SR; Torch IgG pnl; Toxoplasma, Rubella. Cytomegalovirus, Herpes Simplex Virus |
2.77 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
Release 2.77: AnswerListId: removed answerlist; |
0 |
102089-0 |
FHIR resource patient medical record |
Find |
{Setting} |
Pt |
Doc |
|
|
ACTIVE |
FHIR resource patient medical record |
|
MIN |
DefinitionDescription |
|
|
|
|
|
n/a |
|
|
|
DOC.ONTOLOGY |
|
102089-0 |
|
|
|
|
|
|
|
|
0 |
FHIR MR |
|
|
|
N |
|
DOC.ONT; Document; FHIR MR; Finding; Findings; Point in time; Random |
2.79 |
2.75 |
Y |
|
|
|
|
|
|
|
|
|
Release 2.79: ValidHL7AttachmentRequest: Updated to add this term to the HIPAA tab; |
0 |
10209-5 |
Physical findings |
Find |
Neurologic balance+Coordination |
Pt |
Nar |
Observed |
|
ACTIVE |
Physical findings of Neurologic balance and Coordination Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.PX |
|
10209-5 |
|
Observed |
|
|
|
|
|
|
0 |
Phys find Balance+Coordination |
|
|
|
|
|
Bal; Exam; Examination; Finding; Findings; H+P; H+P.PX; Narrative; P prime; Phys find; Point in time; Random; Report |
2.4 |
1.0i |
|
|
|
|
|
|
|
|
|
|
|
0 |
102090-8 |
Ceruloplasmin |
MCnc |
Urine |
24H |
Qn |
|
|
ACTIVE |
Ceruloplasmin [Mass/volume] in 24 hour Urine |
|
ADD |
DefinitionDescription |
|
|
g/dL |
|
|
|
|
|
|
CHEM |
|
102090-8 |
|
|
|
|
Both |
|
|
|
0 |
Ceruloplasmin 24h Ur-mCnc |
|
|
|
N |
|
1 day; 24 hours; 24HR; Caeruloplasmin; Chemistry; Copper oxidase; Cp; Ferroxidase; Level; Mass concentration; QNT; Quan; Quant; Quantitative; UA; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
g/dL |
|
|
|
0 |
102091-6 |
HBA1 & HBA2 gene full mutation analysis |
Find |
Amnio fld/CVS |
Pt |
Doc |
Molgen |
|
ACTIVE |
HBA1 and HBA2 gene full mutation analysis in Amniotic fluid or Chorionic villus sample by Molecular genetics method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
102091-6 |
|
Molgen |
|
|
Both |
|
|
|
0 |
HBA1 + HBA2 Full Mut Anl Amn/CVS |
|
|
|
N |
|
AF; alpha-2 globin; Amn; Amn fl; Amn/CVS; Amnio; Amniotic flu; Amniotic fluid; Chorionic villi; Chorionic villus sample; Document; Finding; Findings; full gene sequencing; Full Mut Anl; HBA1 + HBA2; HBA-T2; HBH; Hemoglobin, alpha 2; Molecular genetics; Molecular pathology; MOLPATH; Mut; Mutations; PCR; Point in time; Random; sequencing of entire coding region |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
102092-4 |
HLA-ABDR typing panel |
- |
Bld/Tiss |
Pt |
- |
|
|
ACTIVE |
HLA-ABDR typing panel - Blood or Tissue |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.HLA |
|
102092-4 |
|
|
|
|
|
|
|
|
0 |
HLA-ABDR typing Bld/T |
|
|
|
N |
|
Blood; HLA ANTIGEN; Human Leukocyte Antigen; Pan; PANEL.HLA; Panl; Pnl; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.77 |
2.77 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
102093-2 |
HLA-ABDR typing panel |
- |
Bld/Tiss^Donor |
Pt |
- |
|
|
ACTIVE |
HLA-ABDR typing panel - Blood or Tissue from Donor |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.HLA |
|
102093-2 |
|
|
|
|
|
|
|
|
0 |
HLA-ABDR typing Bld/T Donr |
|
|
|
N |
|
Blood; Donr; HLA ANTIGEN; Human Leukocyte Antigen; Pan; PANEL.HLA; Panl; Pnl; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.77 |
2.77 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
102096-5 |
HLA-DQA1 SSO panel |
- |
Bld/Tiss |
Pt |
- |
Probe.amp.tar |
|
ACTIVE |
HLA-DQA1 SSO panel - Blood or Tissue by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.HLA |
|
102096-5 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
HLA-DQA1 SSO pnl Bld/T NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; DNA NUCLEIC ACID PROBE; DNA probe; HLA ANTIGEN; HLA-DQA1 SSO pnl; Human Leukocyte Antigen; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Pan; PANEL.HLA; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; SDA; Strand Displacement Amplification; Tissue; Tissue, unspecified; TMA; Transcription mediated amplification; WB; Whole blood; Whole blood or Tissue |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
102097-3 |
Glomerular filtration rate |
ArVRat |
Ser/Plas/Bld |
Pt |
Qn |
Creatinine, Cystatin C and Urea-based formula (CKiD)/1.73 sq M |
|
ACTIVE |
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine, Cystatin C and Urea-based formula (CKiD)/1.73 sq M |
|
NAM |
DefinitionDescription |
|
|
mL/min/1.73 m2 |
|
|
3.98 x [(Height (cm)/100)/(SCr (umol/L)*0.113)]^0.456 x [1.8/CysC (mg/L)]^0.418 x [30/(Urea (mmol/L)]^0.079 x 1.076 (if male) x [Height (cm)/100/1.4]^0.179 |
|
|
|
CHEM |
|
102097-3 |
|
Creatinine, Cystatin C and Urea-based formula (CKiD)/1.73 sq M |
|
|
Both |
|
|
|
0 |
GFR/BSA.pred S/P/B Cr+Cyst+Ur CKD-ArVRat |
|
|
|
N |
|
Blood; Chemistry; Creat+Cyst+Urea CKiD; GFR; Glom; Pl; PlasBld; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; Square Meter; SR; Volume rate/area; Volume Rate/Ratio; WB; Whole blood |
2.79 |
2.75 |
|
|
|
|
|
|
|
mL/min/{1.73_m2} |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: eGFR measurement representation in LOINC had changed in LOINC: Component: Glomerular filtration rate, and Method: .../1.73 sq.M among non-black population or �/1.73 sq.M among black population, and others�.; |
0 |
102098-1 |
Acute myeloid leukemia minimal residual disease |
Find |
Bone mar |
Pt |
Nar |
Flow cytometry |
|
ACTIVE |
Acute myeloid leukemia minimal residual disease in Bone marrow by Flow cytometry (FC) Narrative |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
102098-1 |
|
Flow cytometry |
|
|
Both |
|
|
|
0 |
AML MRD Mar FC |
|
|
|
N |
|
AML; AML MRD; BM; BON; Bone marrow; Dis; Diseases; Dynamic; Dz; FC; Finding; Findings; HEMATOLOGY/CELL COUNTS; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; Myelo; Narrative; Point in time; Random; Report |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
102099-9 |
B-cell acute lymphocytic leukemia |
Find |
Bld/Tiss |
Pt |
Doc |
FISH |
|
ACTIVE |
B-cell acute lymphocytic leukemia in Blood or Tissue by FISH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
102099-9 |
|
FISH |
|
|
Both |
|
|
|
0 |
B-cell ALL Bld/T FISH |
|
|
|
N |
|
B Cell; B-ALL; B-cell acute lymphoblastic leukemia; B-cell ALL; BCELLS; Blood; Document; Finding; Findings; Fluorescent in situ hybridization; Molecular pathology; MOLPATH; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
1021-5 |
E Ag |
PrThr |
RBC |
Pt |
Ord |
|
|
ACTIVE |
E Ag [Presence] on Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
1021-5 |
|
|
|
|
Both |
|
|
|
0 |
E Ag RBC Ql |
|
|
|
|
|
Antigen; Antigens; BLOOD BANK; Erythrocytes; Hematology; Heme; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Red blood cells; Red blood corpusles; Rh Blood Group System; Screen |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
10210-3 |
Physical findings |
Find |
General status |
Pt |
Nar |
Observed |
|
ACTIVE |
Physical findings of General status Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.PX |
|
10210-3 |
|
Observed |
|
|
|
|
|
|
0 |
Phys find General status |
|
|
|
|
|
Exam; Examination; Finding; Findings; H+P; H+P.PX; Narrative; P prime; Phys find; Point in time; Random; Report |
2.63 |
1.0i |
|
|
|
|
|
|
|
|
|
|
|
0 |
102100-5 |
B-cell acute lymphoblastic leukemia |
Find |
Bld/Tiss |
Pt |
Doc |
FISH |
|
ACTIVE |
B-cell acute lymphoblastic leukemia in Blood or Tissue by FISH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
102100-5 |
|
FISH |
|
|
Both |
|
|
|
0 |
B-cell ALL Bld/T FISH |
|
|
|
N |
|
B Cell; B-ALL; B-cell acute lymphoblastic leukemia; B-cell ALL; BCELLS; Blood; Document; Finding; Findings; Fluorescent in situ hybridization; Molecular pathology; MOLPATH; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
102101-3 |
Acute myeloid leukemia |
Find |
Bld/Tiss |
Pt |
Doc |
FISH |
|
ACTIVE |
Acute myeloid leukemia in Blood or Tissue by FISH |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
102101-3 |
|
FISH |
|
|
Both |
|
|
|
0 |
AML Bld/T FISH |
|
|
|
N |
|
AML; Blood; Document; Finding; Findings; Fluorescent in situ hybridization; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Myelo; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
102102-1 |
Vitamin B3 & metabolites panel |
- |
Ser/Plas |
Pt |
- |
LC/MS/MS |
|
ACTIVE |
Vitamin B3 and metabolites panel - Serum or Plasma by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
102102-1 |
|
LC/MS/MS |
|
|
Order |
|
|
|
0 |
Vit B3 + metabolites Pnl SerPl LC/MS/MS |
|
|
|
N |
|
Chemistry; Metabolite; Metb; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Vit B3 + metabolites Pnl |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
102103-9 |
Acute myeloid leukemia panel |
- |
Bld/Tiss |
Pt |
- |
FISH |
|
ACTIVE |
Acute myeloid leukemia panel - Blood or Tissue by FISH |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MOLPATH |
|
102103-9 |
|
FISH |
|
|
Order |
|
|
|
0 |
AML panel Bld/T FISH |
|
|
|
N |
|
AML; AML panel; Blood; Fluorescent in situ hybridization; Molecular pathology; MOLPATH; Myelo; Pan; Panel.molpath; Panl; Pnl; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
102104-7 |
Streptococcus agalactiae |
Susc |
Urine |
Pt |
OrdQn |
Culture |
|
ACTIVE |
Streptococcus agalactiae [Susceptibility] in Urine by Culture |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
102104-7 |
|
Culture |
|
|
Observation |
|
|
|
0 |
Gp B Strep Ur Cult |
|
|
|
N |
|
AST; C&S; Cult; Cultures; GBS; Gp B Strep; Group B; Group B Strep; Microbiology; Point in time; Random; S agalactiae; Steptococcus Group B; Strep; Strep B; Strep group B; Strept; Streptococci group B; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; UA; UR; Urn; Vet; Veterinary |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
102105-4 |
Carya illinoinensis tree Ab.IgG |
MCnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Pecan or Hickory Tree IgG Ab [Mass/volume] in Serum by Immunoassay |
|
ADD |
DefinitionDescription |
|
|
mcg/mL |
|
|
|
|
|
|
ALLERGY |
|
102105-4 |
|
IA |
|
|
Both |
|
|
|
0 |
Pecan/Hick Tree IgG IA-mCnc |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Carya illinoinensis IgG; Carya pecan; EIA; ELFA; ELISA; Enzyme immunoassay; Hickory; IAA; Immune globulin G; Immunoglobulin G; Level; Mass concentration; MEIA; Pecan; Pecan pollen; Pecan/Hick; Pecan/Hick Tree; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; SUDS; t022; t22 |
2.75 |
2.75 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
102106-2 |
Glycolate |
SCnc |
Ser/Plas |
Pt |
Qn |
GC-MS |
|
ACTIVE |
Glycolate [Moles/volume] in Serum or Plasma by Gas chromatography-mass spectrometry |
|
ADD |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
102106-2 |
|
GC-MS |
|
|
Both |
|
|
|
0 |
Glycolate SerPl GC-MS-sCnc |
|
|
|
N |
|
Chemistry; Gas chromatography; Glycolic acid; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.75 |
2.75 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |